Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing medicines for debilitating disorders of the brain. Co.'s principal product, ZULRESSO, is a proprietary intravenous, formulation of brexanolone for the treatment of postpartum depression (PPD). Co.'s other product candidate is zuranolone (SAGE-217), an oral compound that is in Phase 3 clinical development for PPD and major depressive disorder. Co.'s second area of focus is the development of compounds that target the NMDA receptor. The product candidate selected for development from this program is SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor. The SAGE stock yearly return is shown above.
The yearly return on the SAGE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SAGE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|